Christopher Burnley
EnVivo Pharmaceuticals has selected Christopher Burnley as its new chief business officer.
Prior to joining the central nervous system (CNS) therapies specialist, Burnley founded and was CEO of VetRx – a biotech start-up developing human biologics for use in companion animals.
In his new role, he will be responsible for corporate strategy and business development plans.
Kees Been, president and CEO, said: “This is a pivotal time for EnVivo as we continue to advance our pipeline and our lead program.
“Chris' track record of leveraging clinical programs to forge productive and collaborative corporate partnerships will be invaluable as we analyse the strategic options.”